Skip Navigation LinksOA_ADAP_Management_Memo_2020-24-Addition_of_Tamiflu_to_the_ADAP_Formulary

State of Cal Logo
EDMUND G. BROWN JR.
Governor

State of California—Health and Human Services Agency
California Department of Public Health


ADAP MM 2020-24
July 29, 2020


TO:
ADAP ENROLLMENT WORKERS

SUBJECT:
ADDITION OF OSELTAMIVIR PHOSPHATE (TAMIFLU®) TO THE ADAP FORMULARY

​ADAP MANAGEMENT MEMO 2020-24: ADDITION OF OSELTAMIVIR PHOSPHATE (TAMIFLU) TO THE ADAP FORMULARY


Effective July 29, 2020, oseltamivir phosphate (Tamiflu®) has been added to the ADAP formulary. According to guidelines from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices, people living with HIV are considered to be at high risk for serious influenza-related complications. Additionally, the CDC recommends prompt treatment of influenza with antivirals, such as oseltamivir phosphate, to prevent serious influenza complications. For these reasons ADAP has added both the brand and generic forms of oseltamivir phosphate to the ADAP formulary.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of oseltamivir phosphate. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you, 
Sandra_Robinson_E_Signature
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health






Page Last Updated :